Prevalence and natural history of graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1443-1449

  Tanda, M L ^a   Piantanida, E ^a   Liparulo, L ^a   Veronesi, G ^a   Lai, A ^a   Sassi, L ^a   Pariani, N ^a   Gallo, D ^a   Azzolini, C ^a   Ferrario, M ^a   Bartalena, L ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; GLUCOCORTICOID; THIAMAZOLE;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIPLOPIA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPTIC NERVE DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; ALGORITHMS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; HYPERTHYROIDISM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; THYROID FUNCTION TESTS;

EID: 84876244407     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3873     Document Type: Article

References (43)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168-199.
2. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of Graves' orbitopathy. J Clin Endocrinol Metab. 2013;98:145-152.
3. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
4. Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33:414-421.
5. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12:855-860.
6. Bartalena L, Marcocci C, Pinchera A. Graves' ophthalmopathy: a preventable disease? Eur J Endocrinol. 2002;146:457-461.
7. Bartalena L. Prevention of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:371-379.
8. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364:1920-1931.
9. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285.
10. Bartalena L, Tanda ML. Clinical practice: Graves'ophthalmopathy. N Engl J Med. 2009;360:994-1001.
11. Baldeschi L. Rehabilitative surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' Orbitopathy: A Multidisciplinary Approach, Questions and Answers. 2nd rev ed. Basel, Switzerland: Karger; 2010: 167-170.
12. Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26: 339-358.
13. Lazarus JH. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26:273-279.
14. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995; 42:45-50.
15. Noth D, Gebauer M, Müller B, Bürgi U, Diem P. Graves' ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly. 2001;131:603-609.
16. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of aninternational survey. Clin Endocrinol (Oxf). 1998;49:21-28.
17. Laurberg P, Berman DC, Bülow Pedersen I, Andersen S, Carlé A. Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab. 2012;97:2325-2332.
18. Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf). 1999;51:503-508.
19. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992;326:1733-1738.
20. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78.
21. Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700-3707.
22. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349-1352.
23. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: aretrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333-1337.
24. Perros P, Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid. 1998;8:423-425.
25. Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165:899-905.
26. Bartalena L. The dilemma ofhow to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592-599.
27. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh). 1989;121(Suppl 2):185-189.
28. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med. 1990;150: 1098-1101.
29. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130: 494-497.
30. Hägg E, Asplund K. Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed). 1987;295:634-635.
31. Bartalena L, Martino E, Marcocci C, et al. More onsmoking habits and Graves' ophthalmopathy. J Endocrinol Invest. 1989;12:733-737.
32. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA. 1993;269:479-482.
33. Winsa B, Mandahl A, Karlsson FA. Graves' disease, endocrine ophthalmopathy and smoking. Acta Endocrinol (Copenh). 1993;128: 156-160.
34. Bartalena L, Bogazzi F, Tanda ML, Manetti L, Dell'Unto E, Martino E. Cigarette smoking and the thyroid. Eur J Endocrinol. 1995; 133:507-512.
35. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45:477-481.
36. Laurberg P, Berman DC, Andersen S, Bülow Pedersen I. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid. 2011;21:951-956.
37. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid. 2011;21:279-283.
38. Menconi F, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. JClin Endocrinol Metab. 2007;92:1653-1658.
39. Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:E44-E48.
40. De Bellis A, Conzo G, Cennamo G, et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine. 2012; 41:320-326.
41. Tanda ML, Lai A, Bartalena L. Relation between Graves' orbitopathy and radioiodine therapyfor hyperthyroidism: factsand unsolved questions. Clin Endocrinol (Oxf). 2008;69:845-847.
42. Wiersinga WM. Combined thyroid-eye clinics. In: Wiersinga WM, Kahaly GJ, eds. Graves' Orbitopathy: A Multidisciplinary Approach, Questions and Answers. 2nd rev ed. Basel, Switzerland: Karger; 2010:96-99.
43. Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab. 2012;97:4454-4463.